Mingyue Lens (301101): Defocus lenses maintain a high increase in annual performance and remarkable resilience

Core idea: The company publishes the 2023 annual report and the 2024 quarterly report. In '23, the company achieved revenue of 749 million yuan, +20.2% year-on-year; net profit to mother was 158 million yuan, +15.7% year-on-year. Among them,

廣發證券4minutes ago

Moonlight Lens (301101.SZ): No contact lenses have been produced

Gelonghui, April 24 | Mingyue Lens (301101.SZ) said on the interactive platform that the company currently does not produce contact lenses. High-end optical resin lenses are the company's core products, and lens products are mainly based on its own well-known brand “Mingyue”. According to authoritative market research data published by the internationally renowned market research agency Frost & Sullivan (hereinafter referred to as “Sullivan”), in the retail pattern of the Chinese brand lens industry in 2023, in terms of retail volume, Mingyue Lens ranked first with a market share of 12.4%.

Gelonghui Finance15minutes ago

Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in perfo

Dongwu Securities released a research report on April 24 stating that it gave Hengrui Pharmaceutical (600276.SH) a purchase rating. The main reasons for the rating include: 1) continuous implementation of innovative results, driving steady growth in performance; 2) continuous overseas licensing and overseas clinical gains to steadily advance the internationalization process; 3) early R&D capabilities are outstanding, and multiple innovative technology platforms are expected to continuously produce new products. (Mainichi Keizai Shimbun)

Zhitong Finance46minutes ago

A-share changes丨Q1 performance was under pressure, and Puri Ophthalmology once fell more than 11% to a record low

Glonghui, April 24 | Puri Ophthalmology (301239.SZ) once fell by more than 11%. The low was 45.23 yuan, a new low since listing, and its total market capitalization fell below 7 billion yuan. According to news, the company's main revenue for the first quarter was 676 million yuan, up 4.01% year on year; net profit to mother was 16.924,900 yuan, down 89.58% year on year. The company's net profit returned to mother last year was 268 million yuan, an increase of 1202.56% over the previous year. It can be seen from this that the company's performance in the first quarter of this year was clearly under pressure.

Gelonghui Finance14:49

These 4 Measures Indicate That Chongqing Taiji Industry(Group)Ltd (SHSE:600129) Is Using Debt Reasonably Well

Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's balance sheet when you examine how risky it is, since debt is often involved whe

Simply Wall St12:23

The medical services sector opened and fell, and Puri Ophthalmology fell by more than 10%

The medical services sector opened and declined. As of press release, Puri Ophthalmology and Jinkai Biotech had fallen by more than 10%, while Hongbo Pharmaceutical and Huaxia Ophthalmology had followed suit.

Zhitong Finance09:37